Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,300.22 +53.54 (+1.02%) Dow
39,834.30 +276.19 (+0.70%) Nasdaq
16,725.77 +214.59 (+1.30%) Bitcoin USD
65,303.11 +3,948.11 (+6.43%) CMC Crypto 200
1,381.40 +113.45 (+8.95%)
AKRO May 2024 32.500 call
| Previous close | 0.2100 |
| Open | 0.2100 |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 32.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.2100 - 0.2100 |
| Contract range | N/A |
| Volume | |
| Open interest | 418 |
GuruFocus.comAkero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...
Comprehensive Analysis of Financial Performance and Strategic Progress
GlobeNewswireAkero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
-- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll; SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4) on track to be initiated in second quarter of 2024 -- SOUTH SAN FRANCISCO, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Akero Ther
- GlobeNewswire
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024, at 5:00 p.m. P.T. in Las Vegas, NV. A live webcast of the Company presentation will be available through the investor relations sec
